NSI-189 vs PE 22-28
A side-by-side research comparison of NSI-189 and PE 22-28 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | NSI-189 | PE 22-28 |
|---|---|---|
| Full name | NSI-189 Phosphate (Neurogenic Compound) | PE 22-28 (Spadin-Derived TREK-1 Peptide) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Investigational | Research peptide (preclinical) |
| Mechanism | Stimulates hippocampal neural stem cell proliferation and differentiation via Akt/CREB/BDNF signaling. Increases hippocampal volume visible on MRI. | Selectively blocks the TREK-1 background potassium channel. TREK-1 inhibition enhances serotonergic signaling and rapidly increases synaptogenesis and neurogenesis, producing antidepressant-like effects faster than SSRIs in animal models. |
| Molecular weight | 366.4 Da | ~ (7-residue peptide) |
| Half-life | 18-22 hours | Short (peptide; improved vs spadin) |
| Bioavailability | High (oral) | Intranasal or injection (research) |
| Typical dose | 40-80 mg | Not established for humans |
| Frequency | Once daily | Research only |
| Route | Oral | Intranasal or injection (research) |
NSI-189 reported benefits
- Hippocampal neurogenesis
- Measurable brain volume increase
- Cognitive enhancement
- Antidepressant effects
- Long-term neural benefit
PE 22-28 reported benefits
- Rapid antidepressant effects (preclinical)
- Promotes neurogenesis and synaptogenesis
- TREK-1 channel blockade
- Neuroplasticity research interest
Related comparisons
Research and educational reference only. Not medical advice.